Avalo Therapeutics, Inc. (AVTX) Downgraded to Neutral by Guggenheim

Market Context

Avalo Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $6.93 with a market capitalization of $220.3M.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Guggenheim's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Avalo Therapeutics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 23, 2026	Guggenheim	Neutral	N/A
Oct 23, 2026	Wedbush	Outperform	N/A
Oct 23, 2026	HC Wainwright & Co.	Neutral	N/A
Oct 23, 2026	BTIG	Buy	N/A
Aug 07, 2026	Guggenheim	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View AVTX Stock Page